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11 Abstract
12 Individual diﬀerences in emotional processing are likely to contribute to vulnerability and resilience to
13 emotional disorders such as depression and anxiety. Genetic variation is known to contribute to these
14 diﬀerences but they remain incompletely understood. The serotonin transporter (5-HTTLPR) and a2B-
15 adrenergic autoreceptor (ADRA2B) insertion/deletion polymorphisms impact on two separate but inter-
16 acting monaminergic signalling mechanisms that have been implicated in both emotional processing and
17 emotional disorders. Recent studies suggest that the 5-HTTLPR s allele is associated with a negative
18 attentional bias and an increased risk of emotional disorders. However, such complex behavioural traits
19 are likely to exhibit polygenicity, including epistasis. This study examined the contribution of the
20 5-HTTLPR and ADRA2B insertion/deletion polymorphisms to attentional biases for aversive information
21 in 94 healthy male volunteers and found evidence of a signiﬁcant epistatic eﬀect (p<0.001). Speciﬁcally, in
22 the presence of the 5-HTTLPR s allele, the attentional bias for aversive information was attenuated by
23 possession of the ADRA2B deletion variant whereas in the absence of the s allele, the bias was enhanced.
24 These data identify a cognitive mechanism linking genotype-dependent serotonergic and noradrenergic
25 signalling that is likely to have implications for the development of cognitive markers for depression/
26 anxiety as well as therapeutic drug eﬀects and personalized approaches to treatment.
27 Received 10 June 2011 ; Reviewed 7 July 2011 ; Revised 14 July 2011 ; Accepted 20 July 2011
28 Key words : ADRA2B, emotional processing, 5-HTTLPR.
29 Introduction
30 Enhanced processing of emotionally salient in relation
31 to neutral information is normally considered to be an
32 adaptive process enabling threat detection and in-
33 creasing the probability of survival (Vuilleumier,
34 2005). However, there is considerable evidence that
35 biased processing of emotional information also plays
36 a role in the aetiology and maintenance of emotional
37 disorders such as depression and anxiety (Leppanen,
38 2006). The monoamine neurotransmitters (serotonin,
39 dopamine, noradrenaline) are known to play a
40signiﬁcant role in emotional processing and although
41they are generally considered to act synergistically,
42few studies have speciﬁcally investigated interactions
43between these neurotransmitters.
44Serotonin and noradrenaline are also heavily im-
45plicated in the aetiology of emotional disorders and
46the majority of therapeutic agents increase synaptic
47levels of these neurotransmitters (Nutt, 2002). Despite
48their use for over half a century, it remains unclear
49how antidepressants exert their therapeutic eﬀects.
50More recently, evidence has emerged suggesting that
51serotonergic and noradrenergic antidepressant drugs
52may act by modifying emotional processing biases
53(Harmer et al. 2009). Yet in spite of this increasing in-
54sight, the fact that up to 50% of patients treated with
55these medications fail to respond adequately remains
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56 a signiﬁcant challenge in the management of these
57 disorders (Souery et al. 1999). Inter-individual dif-
58 ferences in responses to emotional stimuli may con-
59 tribute to diﬀerences in vulnerability to emotional
60 disorders as well as response to therapeutic agents
61 (Hamann & Canli, 2004). It is increasingly accepted
62 that genetic factors explain small but signiﬁcant
63 amounts of this variability (Todd et al. 2011). Thus,
64 polymorphisms in genes involved in serotonergic and
65 noradrenergic signalling represent apposite candi-
66 dates for further investigation.
67 One of the genetic variants that have been most ex-
68 tensively investigated in relation to human emotional
69 processing and emotional disorders is the gene
70 encoding the serotonin transporter (5-HTTAQ2 or
71 SLC6A4). An insertion/deletion polymorphism in the
72 promoter region of this gene (5-HTTLPR) results in two
73 common allelic variants : short (s) and long (l). The
74 former has been associated with reduced transporter
75 transcription, resulting in approximately 50% re-
76 duction in transporter availability in vitro and pre-
77 sumed increased synaptic serotonin availability (Heils
78 et al. 1996). More recently, an additional A/G single
79 nucleotide polymorphism (SNP) in the l allele (rs25531)
80 has been found to further inﬂuence transcriptional
81 activity. The G variant of the l allele is considered to
82 result in a reduction in transcriptional eﬃciency to a
83 level similar to that of the s allele (Hu et al. 2005;
84 Wendland et al. 2006). However, the frequency of this
85 G allele varies with ethnicity and it is relatively un-
86 common in white European ethnic groups (Hu et al.
87 2006). Early seminal studies linked the s allele to in-
88 creased neurotic personality traits (Lesch et al. 1996)
89 and an increased risk of depression in the context of
90 adverse life events (Caspi et al. 2003). Subsequent
91 studies examining the in-vivo eﬀects of this genetic
92 variation on the phenotypic expression of 5-HTT in the
93 human brain have produced inconsistent results
94 (Praschak-Rieder et al. 2007; Reimold et al. 2007; van
95 Dyck et al. 2004; Willeit et al. 2000). However, consist-
96 ent with a number of previous studies, a relatively
97 large recent positron emission tomography (PET)
98 study in healthy volunteers found that polymorphic
99 variation in 5-HTTLPR did not alter expression of
100 5-HTT (Murthy et al. 2010). It has, however, been sug-
101 gested that this genetic variation instead contributes to
102 early neurodevelopmental changes that may impact
103 on brain structure and function in later life (Lesch &
104 Gutknecht, 2005). This would be consistent with the
105 further body of functional magnetic resonance
106 imaging (fMRI) literature that has more consistently
107 documented that s allele carriers demonstrate signiﬁ-
108 cantly greater amygdala activation in response to
109aversive, relative to neutral, stimuli in a variety of
110emotional processing tasks (Bertolino et al. 2005; Canli
111et al. 2005; Hariri et al. 2002, 2005 ; Heinz et al. 2004;
112Pezawas et al. 2005; for ameta-analysis seeMunafo` et al.
1132008). Yet, the behavioural implications of these neural
114diﬀerences remained unclear. More recently a number
115of studies have focused on ‘behavioural endo-
116phenotypes’ such as selective attentional biases for
117emotional information. To date, these studies have
118demonstrated an association between the 5-HTTLPR s
119allele and preferential attention to aversive stimuli
120(Beevers et al. 2007, 2010, 2011 ; Fox et al. 2009; Osinsky
121et al. 2008), although these reports have not been en-
122tirely consistent (Caspi et al. 2010). One important
123potential source of inconsistency and non-replication
124in genetics studies of complex quantitative traits is the
125issue of polygenicity, including biological epistasis
126(Moore, 2008). However, none of these neuroimaging
127or behavioural genetics studies has examined the ef-
128fects of the other major neurotransmitter system im-
129plicated in aﬀective spectrum disorders and emotional
130processing, i.e. the noradrenergic system.
131Noradrenaline has an established role in modulat-
132ing memory enhancement for emotionally arousing
133information (McGaugh, 2004) and recent pharmaco-
134logical challenge studies indicate that it is also in-
135volved in modulating attentional biases for emotional
136information in healthy human volunteers (De Martino
137et al. 2008). However, the contribution of genetically
138inﬂuenced diﬀerences in noradrenergic tone to inter-
139individual diﬀerences in human emotional processing
140has been largely unexplored. An insertion/deletion
141polymorphism in the a2B-adrenergic (auto)receptor
142gene (ADRA2B) has recently been found to contribute
143to individual diﬀerences in emotionally inﬂuenced
144memory processes. The deletion variant (Del301-303)
145is associated with decreased agonist-promoted phos-
146phorylation and receptor desensitization in vitro
147(Small et al. 2001), presumed to be associated with in-
148creased noradrenergic tone in vivo. In two seminal
149studies, de Quervain and colleagues demonstrated
150an association between this polymorphic variant, in-
151creased amygdala reactivity and an increased memory
152bias for emotional stimuli (de Quervain et al. 2007;
153Rasch et al. 2009). However, the contribution of
154ADRA2B to emotionally enhanced attentional pro-
155cesses was not explored. It therefore remains possible
156that the observed memory bias arises due to an atten-
157tional advantage contributing to enhanced encoding of
158emotional information (Todd et al. 2011). The purpose
159of this study was therefore to test the hypothesis that
160an increased attentional bias for emotionally arousing
161information is associated with the deletion variants of
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162 ADRA2B and 5-HTTLPR and examine whether
163 these eﬀects are subject to additive or non-additive
164 interactions.
165 Materials and methods
166 Participants
167 One hundred and seven healthy white British
168 male volunteers between the ages of 18 and 35 yr
169 (mean¡S.DAQ3 .=24.0¡4.8) were recruited from the uni-
170 versity and local community. They had no lifetime
171 history of psychiatric or neurological disorder. Esti-
172 mates of verbal IQ were derived from the National
173 Adult Reading Test (NART; Nelson, 1982). The study
174 was approved by the local research ethics committee.
175 Following complete description of the study to the
176 participants, written informed consent was obtained.
177 Behavioural task
178 We used an emotional attention blink (AB) task based
179 on dual-target rapid serial visual presentation (RSVP)
180 methodology (Raymond et al. 1992). Identiﬁcation of a
181 ﬁrst target (T1) in a rapid stream of stimuli leads
182 to transient impairment in identiﬁcation of a second
183 target (T2) – an eﬀect, known as the attentional blink.
184 It has previously been used by us and others to dem-
185 onstrate a bias towards accurate detection of aversive
186 T2 targets compared to neutral (Anderson, 2005 ;
187 Anderson & Phelps, 2001 ; De Martino et al. 2008;
188 Gibbs et al. 2007; Keil & Ihssen, 2004). The task com-
189 prised 168 trials, each trial consisting of 13 white dis-
190 tracter words and 2 green target words (T1 and T2)
191 presented sequentially in the centre of a laptop
192 computer screen (see Fig. 1). T1 stimuli were all
193 neutral words averaging 4.8 letters in length. T2
194 words were derived from the Aﬀective Norms for
195 English Words (Bradley & Lawson, 1999) and half
196were aversive-arousing (mean valence and arousal
197ratings of 2.5 and 7.0, respectively) and half were
198neutral (mean valence and arousal ratings of 5.1 and
1993.5, respectively). Aversive and neutral T2 stimuli did
200not diﬀer signiﬁcantly in letter length (mean=5.1 vs.
2014.8, respectively, p=0.21) or written word frequency
202(mean=67.1 vs. 87.9, respectively, p=0.50) (Kucera &
203Francis, 1967). Distracter items were 92 words of
204longer length (mean letters=12.5) to facilitate masking
205of the targets. Each item was presented for 100 ms and
206was immediately followed by the subsequent item.
207The lag between the T1 and T2 targets was varied to
208contain one, three, or ﬁve intervening distracters (lag
2092, lag 4 or lag 6) with corresponding stimulus onset
210asynchronies (SOAs) of 200 ms, 400 ms or 600 ms.
211Participants were instructed to ignore the words in
212white (distracters) and identify the two green target
213words (T1 and T2). Responses were made by partici-
214pants writing down the two targets in any order
215immediately after each trial on sheets that were sub-
216sequently scored. Exact correct spelling was not
217necessary for a correct response. Vowel and consonant
218omissions, insertions or replacements were allowed
219provided the word was recognizable and the spelling
220was phonologically accurate.
221Genotyping
222DNA extraction and genotyping for the ADRA2B in-
223sertion/deletion polymorphism was performed by
224KBioscience, Hertfordshire, UK as previously reported
225(Gibbs et al. 2010). For the 5-HTTLPR insertion/
226deletion, polymerase chain reaction (PCR) was also
227performed using KBioscience’s in-house SNP geno-
228typing system (KASPar1) using ﬂuorescently labelled
229primers (pF1: Cy5.5-CCCAGCGTGCTCCAGAAAC;
230pR: GGACCTGGGCAGTTGTGC). For technical
231reasons, we were unable to complete further tri-allelic
232genotyping of the A/G SNP (rs25531) in the
2335-HTTLPR insertion allele.
234Statistical analysis
235Hardy–Weinberg equilibrium (HWE) of genetic data
236was assessed by x2 analysis. Possible genotype-
237dependent diﬀerences in demographic variables
238between genotype groups were assessed in a multi-
239variate analysis of variance (ANOVA) with age and IQ
240as dependent variables and 5-HTTLPR and ADRA2B
241genotypes as between-subjects factors. Genotype ef-
242fects on T1 detection in the AB task were examined in
243a univariate ANOVA with percent correct T1 report as
244the dependent measure and 5-HTTLPR and ADRA2B
245genotypes as the between-subjects factors. Aﬀective
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Fig. 1. Schematic representation of attentional blink task.
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246 modulation of the AB eﬀect was examined in a
247 repeated-measures ANOVA with the same between-
248 subjects factors, valence (aversive, neutral) and lag
249 (2, 4, 6) as within-subject factors and percent correct T2
250 report (contingent on the correct identiﬁcation of T1)#
251 as the dependent measure. Signiﬁcant interactions
252 were explored using post-hoc t tests. A Greenhouse–
253 Geisser correction was applied where sphericity as-
254 sumptions were violated.
255 Results
256 Genotypes
257 Of the 107 participants, ADRA2B genotypes were un-
258 available for two participants, 11 were homozygous
259 carriers of the ADRA2B deletion, 48 were hetero-
260 zygotes and 46 were non-carriers, consistent with
261 HWE (x2=0.09, p=0.77). Due to the small number of
262 homozygous carriers, they were combined with the
263 heterozygotes, giving two genotype groups of deletion
264 carriers (Del) and non-carriers (Ins) as previously done
265 by us and others (de Quervain et al. 2007; Gibbs et al.
266 2010). For 5-HTTLPR, 12 genotypes were unavailable,
267 35 were homozygous l/l, 41 were heterozygous s/l
268 and 19 were homozygous s/s, consistent with HWE
269 (x2=1.18, p=0.28). Given that the s allele is considered
270 to have a dominant eﬀect (Lesch et al. 1996), partici-
271 pants were divided into two groups: homozygous or
272 heterozygous s allele carriers (S group) and non-
273 carriers (L group) consistent with previous studies
274 (Canli et al. 2005). Participants for whom genetic data
275 were not available for both polymorphisms were ex-
276 cluded from further analysis, leaving a total sample of
277 94. Demographic characteristics (age and IQ) are given
278 in Table 1. There were no genotype eﬀects on these
279 variables.
280Behavioural data
281There was a signiﬁcant main eﬀect of valence on T2
282detection accuracy [F(1, 90)=11.0, p=0.001], with
283greater detection of aversive (92.7¡1.6%) compared to
284neutral (81.2¡1.2%) words. T2 detection accuracy also
285increased signiﬁcantly [F(1.2, 109.4)=183.3, p<0.001]
286as the temporal lag between the targets increased [lag
2872=64.4¡22.2%; lag 4=83.8¡15.7%; lag 6=91.1¡
28812.3%] and there was a signiﬁcant lagrvalence inter-
289action [F(2, 180=28.5, p<0.001] such that the
290emotional attentional bias was most pronounced at lag
2914 (9%) compared to lag 6 (3%) and lag 2 (x3%) where
292it was absent. There were no main eﬀects of the indi-
293vidual genes ; however, there was a highly signiﬁcant
294ADRA2Br5-HTTLPRrvalence interaction [F(1, 90)=
29515.0, p<0.001]. In order to clarify this interaction we
296ﬁrst conducted a separate repeated-measures ANOVA
297in the 5-HTTLPR S and L groups with T2 detection as
298the dependent variable, valence (aversive, neutral) as
299the between-subjects variable and ADRA2B genotype
300as the between-subjects variable. We found signiﬁcant
301ADRA2Brvalence interactions in both 5-HTLPR S
302[F(1, 58)=8.2, p=0.006] and L [F(1, 32)=6.06, p=0.02]
303groups. Post-hoc paired t tests demonstrated that in the
3045-HTTLPR L group, there was a signiﬁcant attentional
305bias for aversive vs. neutral T2 words in ADRA2B
306deletion carriers [t(20)=3.0, p=0.007, d=0.7] that was
307absent in non-carriers [t(12)=x0.68, p=0.504].
308Conversely, in the 5-HTTLPR S group, the signiﬁcant
309emotional attentional bias was absent in ADRA2B de-
310letion carriers [t(29)=0.477, p=0.637] but present in
311non-carriers [t(29)=4.9, p<0.001, d=1] (see Fig. 2).
312There were no other signiﬁcant main genotype eﬀects
313or interactions in relation to T1 or T2 detection.
314Discussion
315The purpose of this study was to examine the
316eﬀects of serotonergic (5-HTTLPR) and noradrenergic
317(ADRA2B) genetic variants on attentional biases
318for aversive stimuli using an attentional blink (AB)
Table 1. Demographic characteristics for 5-HTTLPR and ADRA2B genotypes
5-HTTLPR ADRA2B
S L F p Del Ins F p
Number of participants 34 60 – – 51 43 – –
Age, yr mean (S.D.) 23.9 (4.9) 23.9 (4.3) 0.02 (x) 0.88 (x) 24.7 (4.9) 23.0 (4.3) 1.18 (x) 0.31 (x)
IQ mean (S.D.) 105.9 (6.5) 104.4 (7.0) 2.28 (x) 0.14 (x) 106.7 (5.7) 104.7 (6.4) 3.01 (x) 0.06 (x)
# This is to guarantee that proper attention has been devoted to T1 to
ensure an AB eﬀect.
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319 paradigm. To our knowledge, this is the ﬁrst study to
320 examine the contribution of the ADRA2B insertion/
321 deletion polymorphism to individual diﬀerences in
322 emotional attentional biases and only the second study
323 to explore the genetic basis of the emotional AB eﬀect
324 [Munafo` and colleagues previously found an associ-
325 ation between 5-HTTLPR genotype, smoking status
326 and detection of smoking-related stimuli in an AB task
327 (Munafo` et al. 2005)]. The signiﬁcant novel ﬁnding
328 from this study is that the aﬀective modulation of T2
329 detection is inﬂuenced by a non-additive (epistatic)
330 interaction between the ADRA2B and 5-HTTLPR in-
331 sertion/deletion polymorphisms.
332 Speciﬁcally, we found that a signiﬁcant attentional
333 bias for aversive compared to neutral information was
334 present in individuals possessing at least one copy of
335 the short (s) allele of 5-HTTLPR, but only if they did
336 not carry the ADRA2B deletion. Conversely, the at-
337 tentional bias for emotional information was only
338 present in 5-HTTLPR long (l) allele homozygotes if
339 they were ADRA2B deletion carriers. This suggests
340 that in the presence of the 5-HTTLPR s allele which is a
341 putative risk allele for depressive and anxiety dis-
342 orders, the negative attentional bias is attenuated by
343 the ADRA2B deletion variant whereas in the absence
344 of the s allele, the bias is enhanced. Both of these eﬀects
345 may be related to adaptive processes. For instance,
346 dependent on 5-HTTLPR genotype, the eﬀect of the
347 ADRA2B deletion variant may be to either exert a
348 protective eﬀect against aﬀective spectrum disorders
349 or facilitate enhanced detection of threat, in both cases
350 contributing to increased probability of survival.
351 Behavioural genetics implications
352 We did not ﬁnd a main eﬀect of the serotonin trans-
353 porter polymorphismAQ4 on emotional attention as a
354 number of previous studies have done (Beevers et al.
355 2007; Fox et al. 2009; Munafo` et al. 2005; Osinsky et al.
3562008). However, with the exception of Munafo` et al.
357(2005), all of these studies used a variation of the dot
358probe task to evaluate emotional biases in selective
359attention, rather than the AB task. Although both of
360these tasks evaluate selective attention when cognitive
361resources are limited, the latter measures deployment
362of attention resources under temporal constrains
363while the former typically utilizes spatial limitations.
364Notably, Munafo` et al. (2005) also used an alternate
365variant of the AB task that indexes attention by estab-
366lishing whether the detection of a neutral T2 target is
367impaired when preceding an emotionally salient or
368neutral T1 target. It is possible that these task-related
369diﬀerences may account for the diﬀerence in ﬁndings.
370Yet the studies reporting positive associations using
371the dot probe task are not without inconsistencies. For
372example some have linked the s allele to biases towards
373aversive stimuli (Beevers et al. 2007; Osinsky et al.
3742008) while others suggest that the l allele results
375in biases away from negative stimuli (Fox et al. 2009;
376Kwang et al. 2010). Other discrepancies include
3775-HTTLPR associations found only with long (Osinsky
378et al. 2008) or short (Beevers et al. 2007) stimulus pres-
379entation durations. In spite of using shared dot probe
380methodology, there are still signiﬁcant diﬀerences
381between these studies in terms of subjects (healthy
382volunteers vs. psychiatric patients ; men vs. women),
383stimuli (words vs. spiders vs. pictorial scenes) and
384duration of stimulus presentation (<500 ms vs.
385>500 ms). These diﬀerences highlight the need for
386task consistency in future studies in order to facilitate
387replication (NCI-NHGRI Working Group on
388Replication in Association Studies, 2007).
389The eﬀect of the ADRA2B insertion/deletion
390polymorphism on attentional biases for emotional
391information has not been previously investigated.
392However, it has been suggested that it might contrib-
393ute to the emotional memory bias observed in
394ADRA2B deletion carriers (Todd & Anderson, 2009).
395We did not ﬁnd any main eﬀect of ADRA2B on
396emotional attention in this study suggesting that the
397ADRA2B deletion variant does not independently bias
398attention towards emotional stimuli but may interact
399with other monaminergic gene systems to contribute
400to such bias.
401Behavioural pharmacogenetics implications
402A number of studies have begun to examine possible
403interactions between 5-HTTLPR polymorphisms,
404emotional attentional biases and the eﬀects of sero-
405tonergic manipulation by acute tryptophan depletion
406(ATD) but have thus far failed to produce consistent
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407 ﬁndings (Firk & Markus, 2009 ; Markus & De Raedt,
408 2011; Markus & Firk, 2009 ; Roiser et al. 2007). This
409 may in part be due to the fact that ATD in healthy
410 volunteers, independent of genotype, has not pro-
411 duced entirely consistent eﬀects on emotional pro-
412 cessing (Hayward et al. 2005; Murphy et al. 2002;
413 Rubinsztein et al. 2001). No studies have as yet exam-
414 ined the possible contribution of genetic variation to
415 the eﬀects of serotonergic and noradrenergic drugs on
416 emotional attention. However, a number of pharma-
417 cological studies have examined the eﬀects of sero-
418 tonergic and noradrenergic drugs on emotional
419 processing in healthy subjects (Arce et al. 2008; Arnone
420 et al. 2009; Bru¨hl et al. 2009; Harmer et al. 2008, 2003,
421 2004; Murphy et al. 2009a ; Norbury et al. 2007;
422 Rawlings et al. 2010). This work may be relevant to
423 understanding the present ﬁndings; however, it is
424 diﬃcult to make direct comparisons between geneti-
425 cally and pharmacologically mediated eﬀects on
426 emotional processing as highlighted in the Clinical
427 implications subsection below. Additionally, only
428 three of these studies have speciﬁcally examined at-
429 tentional biases and these have produced relatively
430 inconsistent ﬁndings (Browning et al. 2007; De
431 Martino et al. 2008; Murphy et al. 2009b).
432 Using a dot probe task, Browning et al. (2007) found
433 that the administration of a single dose of the selective
434 serotonin reuptake inhibitor (SSRI) antidepressant
435 citalopram to healthy volunteers resulted in an atten-
436 tional bias towards positive words (Browning et al.
437 2007). This is consistent with some of the behavioural
438 ﬁndings in relation to the 5-HTTLPR l allele described
439 above. On an AB task, De Martino and colleagues
440 found that a single dose of the noradrenaline reuptake
441 inhibitor (NRI) reboxetine boosted detection of
442 emotionally arousing compared to neutral words in
443 healthy volunteers (De Martino et al. 2008). Also on a
444 dot probe task in healthy volunteers, Murphy et al.
445 (2009a, b) found that repeated citalopram adminis-
446 tration reduced the attentional bias towards emotional
447 faces, independently of valence, while reboxetine had
448 no eﬀect (Murphy et al. 2009b). These apparently con-
449 ﬂicting ﬁndings could again be related to diﬀerences
450 in methodology (dot probe vs. AB, words vs. faces,
451 single vs. repeated dosing). In fact, there is evidence
452 from both animal and human studies that acute and
453 chronic citalopram administration may diﬀerentially
454 inﬂuence emotional processing such that acute
455 doses result in an initial increase in the processing
456 of negative information that is attenuated with re-
457 peated dosing (Burghardt et al. 2004; Harmer et al.
458 2003, 2004). However genotype-dependent drug
459 eﬀects may also contribute to these diﬀerences. For
460example, pharmacological enhancement or attenu-
461ation of emotional attentional biases may be less
462prominent in individuals with genotype-related
463emotional processing biases or in whom such biases
464are absent, respectively. If emotional attentional bias is
465to function as an eﬀective cognitive marker, future
466pharmacological challenge studies will also need to
467consider the contribution of genetic variations in the
468neurotransmitter systems under investigation. There
469is also an increasing need to evaluate the eﬀects of
470genetic epistasis between these systems as this may
471have important clinical implications for the pharma-
472cogenetics of depression and anxiety.
473Clinical implications
474That such biological epistasis exists between sero-
475tonergic and noradrenergic genes, is consistent with
476the fact that these neurotransmitter systems are inti-
477mately connected in the central nervous system
478(de Boer, 1995). Noradrenergic neurotransmission is
479modulated by presynaptic inhibitory a2-adrenergic
480(auto)receptors and their blockade increases synaptic
481levels of noradrenaline. However, there is evi-
482dence that serotonergic neurotransmission is also
483modulated by presynaptic a2-adrenergic (hetero)-
484receptors (Clement et al. 1992; De Boer et al. 1994;
485Mongeau et al. 1993). Yet precisely how these systems
486may interact to produce the intermediate phenotypes
487and the clinical disorders themselves remains unclear.
488The fact that the majority of drugs used to treat af-
489fective spectrum disorders act by inhibiting the 5-HTT
490seems at odds with the fact that individuals with
491genetically inﬂuenced reductions in 5-HTT function
492have greater risks of developing these disorders, as
493well as poorer treatment response rates (Lesch &
494Gutknecht, 2005). This ostensible contradiction is in-
495creasingly understood in terms of the complex auto-
496regulatory processes governing serotonergic function
497(Routledge & Middlemiss, 1996) and the potentially
498deleterious neurodevelopmental eﬀects of excessive
499intra-synaptic accumulation of serotonin (Lesch &
500Gutknecht, 2005). Via its intimate relationship with
501serotonergic signalling, the ADRA2B polymorphism
502may also exert its epistatic eﬀects via these auto-
503regulatory and neurodevelopmental mechanisms.
504While this hypothesis warrants further investi-
505gation, the biological epistasis suggested in the present
506study may have important implications for individual
507responses to serotonergic and noradrenergic anti-
508depressant drugs. Most pharmacogenetics studies
509in depression have focused on variations in 5-HTT
510(Schosser & Kasper, 2009 ; Serretti et al. 2007).
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511 However, two large recent projects (STAR*D and
512 GENDEP) have found associations between anti-
513 depressant response and a number of candidate genes
514 involved in both serotonin and noradrenaline signal-
515 ling (Hu et al. 2007; McMahon et al. 2006; Paddock et al.
516 2007; Uher et al. 2009), although none of these studies
517 included the ADRA2B polymorphism. The GENDEP
518 project did examine a polymorphism in the related
519 ADRA2A gene encoding a2A-adrenoceptor subtype
520 but failed to ﬁnd any signiﬁcant eﬀect despite a
521 previously reported association with the response
522 to the serotonin-noradrenaline reuptake inhibitor
523 milnacipran (Wakeno et al. 2008). Of note, neither of
524 the two antidepressants evaluated in GENDEP was a
525 molecular target of the a2-adrenoceptor group.
526 Thus, the role of polymorphic variation in a2-
527 adrenergic receptors (and their interaction with sero-
528 tonergic targets) in the therapeutic response of
529 patients with aﬀective spectrum disorders warrants
530 further investigation.
531 Study limitations
532 The purpose of this study was to investigate epistatic
533 eﬀects of serotonergic and noradrenergic genes on
534 emotional attentional biases. However, the fact that we
535 measured only two polymorphisms out of a number
536 that might contribute to the behavioural eﬀect of in-
537 terest represents a limitation to this study. Most sig-
538 niﬁcantly, we were unable to genotype the additional
539 rs25531 SNP in the long allele of the 5-HTT gene.
540 However, given that the prevalence of the LG allele
541 is low (y10%), this is unlikely to have signiﬁcantly
542 biased our ﬁndings. A further limitation is that al-
543 though the overall sample size was reasonable, there
544 were relatively few individuals in some genotype
545 combinations. This is a particular diﬃculty inherent in
546 measuring epistatic gene eﬀects (Moore, 2008). Future
547 studies will need to use large sample sizes and evolv-
548 ing methodologies to eﬀectively evaluate the likely
549 eﬀects on emotional processing of multiple gene in-
550 teractions (Cordell, 2009). The ﬁnal limitation is that
551 we only used aversive stimuli and male volunteers.
552 While the latter eliminated possible biases associated
553 with gender diﬀerences in emotional processing, it
554 limits the generalizability of our ﬁndings. It is there-
555 fore unclear whether the observed biases are valence
556 and/or gender speciﬁc. Additionally the aversive
557 stimuli used included range of negative emotions
558 (disgust, fear, sadness) rather than speciﬁcally dys-
559 phoric or threat-related emotions. It is therefore un-
560 clear how these processing biases might map onto
561 those considered to relate to depression and anxiety
562disorders. Further studies with larger sample sizes
563including men and women will be required to repli-
564cate and extend our ﬁndings.
565Conclusions
566In spite of these limitations, this study begins to con-
567tribute to the understanding of multiple gene eﬀects
568and interactions in an established cognitive marker for
569aﬀective spectrum disorders – the negative attentional
570bias. It further underlines the potential utility of
571adopting the ‘endophenotype’ approach in pharma-
572cogenetics studies, i.e. examining the genetic factors
573underlying not only the clinical response but also re-
574sponses in cognitive and neural markers. One signiﬁ-
575cant challenge for such studies will be to delineate
576the interaction between potential neurodevelopmental
577eﬀects of genetic polymorphisms inﬂuencing brain
578neurotransmitter systems and the acute/sub-acute
579eﬀects of drug administration. Knockout and trans-
580genic mouse models are likely to be useful in
581appreciating the dynamics of the behavioural–
582psychopharmacogenetic–neurodevelopmental inter-
583face.
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